Risperdal Study Highlights Risk of Gynecomastia Breast Growth
New research presented last weekend that adds to the growing body of evidence in support of Risperdal lawsuits filed on behalf of boys and young men diagnosed with gynecomastia or male breast growth after using the popular medication.
According to the findings of a Risperdal study presented at the 2014 Annual Meeting of the American Association for Geriatric Psychiatry, users of Risperdal may face a 69% increased risk of gynecomastia breast growth when compared to non-users.
A similar increased risk was seen with side effects of Invega, another atypical antipsychotic medication that is similar to Risperdal. However, the same risk was not seen when looking at use of Seroquel and Zyprexa. Researchers indicate that when use of Risperdal or Invega were compared to use of Seroquel or Zyprexa, the risk was still 41% and 40% higher, respectively.
The lawyers at Saiontz & Kirk, P.A. represent individuals throughout the United States who have experienced problems with gynecomastia from Risperdal, which can cause unwanted and psychologically scarring breast growth that has a major impact on a young man’s quality of life.
Risperdal (risperidone) is part of the popular class of medications known as atypical antipsychotics, and the medication has been widely used by children in recent years for bi-polar disorders, autism, irritability, aggression and behavior disorders.
While known side effects of Risperdal may include a risk of weigh gain, the drug makers failed to adequately research the long-term impact of the mediation on boys and the risk of breast development.
Gynecomastia involves the abnormal development of mammary glands, leading to breast development. Symptoms of Risperdal gynecomastia may start with the development of puffy or enlarged nipples, potentially leading to the growth of full breasts. In addition to the psychological impact of this problem, many boys or young men are required to undergo breast removal surgery.
Due to the Risperdal risk of gynecomastia, researchers in this latest study are calling on doctors to prescribe Zyprexa or Seroquel to males, in order to reduce the chances of boys developing breasts while taking Risperdal or Invega.
As a result of the drug maker’s failure to disclose this serious risk or conduct adequate studies before marketing the medication to children, the Risperdal gynecomastia lawyers at Saiontz & Kirk, P.A. are reviewing potential claims for children throughout the United States who have experienced breast growth.
To review a potential claim for yourself, a friend or family member, request a free and confidential claim evaluation.
No Comments • Add Your Comments